利瑞喹尼
化合物
利瑞喹尼(英語:Lirequinil,開發代號:Ro41-3696)是一種非苯二氮䓬類催眠藥,可與GABAA受體上的苯二氮䓬位點結合。在人體臨床試驗中,利瑞喹尼被發現具有與唑吡坦相似的療效,但笨拙和記憶障礙等副作用較少。然而,它的作用也比唑吡坦慢得多,口服給藥後2.5小時才達到血漿峰值濃度,其O-去乙基代謝物Ro41-3290也具有活性,半衰期為8小時。[1][2][3][4]這意味着雖然作為催眠藥有效,但由於產生更多的次日鎮靜作用,利瑞喹尼未能證明優於唑吡坦,因此它尚未被用於臨床。它是由羅氏的一個團隊在1990年代開發的。[5]
臨床資料 | |
---|---|
ATC碼 |
|
識別資訊 | |
| |
CAS號 | 143943-73-1 |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
化學資訊 | |
化學式 | C26H25ClN2O3 |
摩爾質量 | 448.95 g·mol−1 |
3D模型(JSmol) | |
| |
|
參考資料
編輯- ^ Dingemanse J, Bury M, Roncari G, Zell M, Gieschke R, Gaillard AW, Odink J, van Brummelen P. Pharmacokinetics and pharmacodynamics of Ro 41-3696, a novel nonbenzodiazepine hypnotic. Journal of Clinical Pharmacology. August 1995, 35 (8): 821–9. PMID 8522640. S2CID 20456430. doi:10.1002/j.1552-4604.1995.tb04126.x.
- ^ Dingemanse J, Bury M, Bock J, Joubert P. Comparative pharmacodynamics of Ro 41-3696, a new hypnotic, and zolpidem after night-time administration to healthy subjects. Psychopharmacology. November 1995, 122 (2): 169–74. PMID 8848532. S2CID 11960902. doi:10.1007/BF02246091.
- ^ Dingemanse J, Bury M, Hussain Y, van Giersbergen P. Comparative tolerability, pharmacodynamics, and pharmacokinetics of a metabolite of a quinolizinone hypnotic and zolpidem in healthy subjects. Drug Metabolism and Disposition. December 2000, 28 (12): 1411–6. PMID 11095577.
- ^ Dingemanse J, Pedrazzetti E, van Giersbergen PL. Multiple-dose tolerability, pharmacodynamics, and pharmacokinetics of the quinolizinone hypnotic Ro 41-3696 in elderly subjects. Clinical Neuropharmacology. 2001, 24 (2): 82–90. PMID 11307042. S2CID 21588500. doi:10.1097/00002826-200103000-00003.
- ^ US Patent 5561233 Process for the preparation of an intermediate of a benzo[a]quinolizinone derivative